Impact of Total Parenteral Nutrition on Gut Microbiota in Pediatric Population Suffering Intestinal Disorders
Metadatos
Mostrar el registro completo del ítemAutor
Cerdó, Tomás; García Santos, José Antonio; Rodríguez-Pöhnlein, Anna; García Ricobaraza, María; Nieto-Ruiz, Ana; García Bermúdez, María Mercedes; Campoy Folgoso, CristinaEditorial
MDPI
Materia
total parenteral nutrition (TPN) gut microbiota dysbiosis pediatric population
Fecha
2022-11-06Referencia bibliográfica
Cerdó, T. et. al. Nutrients 2022, 14, 4691. [https://doi.org/10.3390/nu14214691]
Patrocinador
’Sara Borrell’ programmes (CD21/00187) from Institute of Health Carlos III (ISCIII); Ministry of Economic Transformation, Industry, Knowledge and University of the Junta de Andalucía (Andalusian Plan for Research, Development and Innovation, PAIDI 2020); young research staff at the University of Granada, funded by the Operational Programme for Youth Employment of the Junta de Andalucía through the Youth Employment Initiative (YEI) and the European Social FundResumen
Parenteral nutrition (PN) is a life-saving therapy providing nutritional support in patients
with digestive tract complications, particularly in preterm neonates due to their gut immaturity during
the first postnatal weeks. Despite this, PN can also result in several gastrointestinal complications
that are the cause or consequence of gut mucosal atrophy and gut microbiota dysbiosis, which may
further aggravate gastrointestinal disorders. Consequently, the use of PN presents many unique
challenges, notably in terms of the potential role of the gut microbiota on the functional and clinical
outcomes associated with the long-term use of PN. In this review, we synthesize the current evidence
on the effects of PN on gut microbiome in infants and children suffering from diverse gastrointestinal
diseases, including necrotizing enterocolitis (NEC), short bowel syndrome (SBS) and subsequent
intestinal failure, liver disease and inflammatory bowel disease (IBD). Moreover, we discuss the
potential use of pre-, pro- and/or synbiotics as promising therapeutic strategies to reduce the risk of
severe gastrointestinal disorders and mortality. The findings discussed here highlight the need for
more well-designed studies, and harmonize the methods and its interpretation, which are critical
to better understand the role of the gut microbiota in PN-related diseases and the development of
efficient and personalized approaches based on pro- and/or prebiotics.